Preclinical evaluation of novel CDK4/6 inhibitor GLR2007 in glioblastoma models.

e14023Background: Glioblastoma multiforme (GBM) is characterized by a high frequency of cyclin-dependent kinase (CDK)4 and CDK6 pathway dysregulation. CDK4/6 inhibitors palbociclib and abemaciclib ...